• +1-646-491-9876
    • +91-20-67278686

    Search

    Candidiasis - Pipeline Review, H1 2017

    Candidiasis - Pipeline Review, H1 2017

    • Report Code ID: RW0001709496
    • Category Pharmaceuticals
    • No. of Pages 147
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Candidiasis - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Candidiasis - Pipeline Review, H1 2017, provides an overview of the Candidiasis (Infectious Disease) pipeline landscape.

    Candidiasis is caused by infection with species of the genus Candida, predominantly with Candida albicans. A Candida infection of the skin appears as a clearly defined patch of red, itchy skin, often leaking fluid. Scabs and pustules may be seen around the edge of the rash. It will usually be found in areas such as the groin, the folds of the buttocks, between the breasts, toes, or fingers, and in the navel. Treatment includes anti fungal drugs.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Candidiasis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Candidiasis (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Candidiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 4, 20 and 10 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 10 and 9 molecules, respectively.

    Candidiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Candidiasis (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Candidiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Candidiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Candidiasis (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Candidiasis (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Candidiasis (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Candidiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 5
    List of Figures 6
    Introduction 7
    Publisher Report Coverage 7
    Candidiasis - Overview 8
    Candidiasis - Therapeutics Development 9
    Pipeline Overview 9
    Pipeline by Companies 10
    Pipeline by Universities/Institutes 13
    Products under Development by Companies 15
    Products under Development by Universities/Institutes 18
    Candidiasis - Therapeutics Assessment 19
    Assessment by Target 19
    Assessment by Mechanism of Action 21
    Assessment by Route of Administration 23
    Assessment by Molecule Type 25
    Candidiasis - Companies Involved in Therapeutics Development 27
    Amplyx Pharmaceuticals Inc 27
    Bakker Medical Srl 27
    Biomar Microbial Technologies 28
    Biosergen AS 28
    Cidara Therapeutics Inc 29
    CSA Biotechnologies LLC 29
    Daewoong Pharmaceutical Co Ltd 30
    Dermala Inc 30
    General Biologicals Corp 31
    Grupo Ferrer Internacional SA 31
    Hsiri Therapeutics LLC 32
    iCo Therapeutics Inc. 32
    ImmunoClin Corp 33
    Matinas BioPharma Holdings Inc 33
    Nanomerics Ltd 34
    NovaDigm Therapeutics Inc 34
    Novartis AG 35
    Onxeo SA 35
    Scynexis Inc 36
    Sealife PHARMA GMBH 36
    Viamet Pharmaceuticals Inc 37
    Visterra Inc 37
    Wellstat Vaccines LLC 38
    Candidiasis - Drug Profiles 39
    (clotrimazole + diclofenac sodium) - Drug Profile 39
    61894700 - Drug Profile 40
    AC-17 - Drug Profile 41
    amphotericin B - Drug Profile 42
    amphotericin B - Drug Profile 44
    amphotericin B - Drug Profile 48
    Amphotericin B sodium - Drug Profile 49
    Antibody to Target Ece1 for Candidiasis - Drug Profile 51
    APX-001 - Drug Profile 52
    APX-001A - Drug Profile 54
    arasertaconazole - Drug Profile 55
    B-4010 - Drug Profile 56
    BL-5923 - Drug Profile 57
    BSG-005 - Drug Profile 58
    candidiasis vaccine - Drug Profile 59
    CD-101 - Drug Profile 60
    Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile 64
    CSA-13 - Drug Profile 65
    Drug for Candidiasis - Drug Profile 67
    DWP-06081 - Drug Profile 68
    Forazoline A - Drug Profile 69
    iCo-010 - Drug Profile 70
    interleukin-22 - Drug Profile 71
    JSM-11 - Drug Profile 72
    KSL-W - Drug Profile 73
    miconazole nitrate - Drug Profile 74
    Monoclonal Antibodies for Candidiasis - Drug Profile 76
    Monoclonal Antibody for Candidiasis - Drug Profile 77
    Monoclonal Antibody for Candidiasis and Gram-Positive Bacterial Infections - Drug Profile 78
    mutanobactin A - Drug Profile 79
    NDV-3 - Drug Profile 80
    NDV-3A - Drug Profile 82
    NP-339 - Drug Profile 84
    obliquumol - Drug Profile 85
    Occidiofungin - Drug Profile 86
    P-113Du - Drug Profile 87
    P-113Tri - Drug Profile 88
    PAC-113 - Drug Profile 89
    Polymers for Clostridium difficile Infections and Candidiasis - Drug Profile 91
    Prof-002 - Drug Profile 92
    Recombinant Enzyme for Candidiasis - Drug Profile 93
    Recombinant Peptides for Oropharyngeal Candidiasis - Drug Profile 94
    SCY-078 - Drug Profile 95
    SLP-0901 - Drug Profile 100
    SLP-0904 - Drug Profile 101
    Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile 102
    Small Molecule for Fungal Infections - Drug Profile 103
    Small Molecules for Aspergillosis and Candidiasis - Drug Profile 104
    Small Molecules for Candidiasis - Drug Profile 105
    Small Molecules for Candidiasis - Drug Profile 106
    Small Molecules for Candidiasis - Drug Profile 107
    Small Molecules for Fungal Infections - Drug Profile 108
    Small Molecules for Fungal Infections - Drug Profile 109
    Small Molecules for Systemic Candidiasis - Drug Profile 110
    Synthetic Peptide to Inhibit CBL-B for Candidiasis - Drug Profile 111
    Synthetic Peptides for Candidiasis - Drug Profile 112
    Synthetic Peptides for Infections Diseases and Oncology - Drug Profile 113
    TOL-463 - Drug Profile 114
    Vaccine to Target Ece1 for Candidiasis - Drug Profile 115
    Vaccine to Target Glucosylceramide for Fungal Infections - Drug Profile 116
    VIS-FNG - Drug Profile 117
    VT-1129 - Drug Profile 118
    VT-1161 - Drug Profile 120
    Candidiasis - Dormant Projects 126
    Candidiasis - Discontinued Products 129
    Candidiasis - Product Development Milestones 130
    Featured News & Press Releases 130
    Appendix 141
    Methodology 141
    Coverage 141
    Secondary Research 141
    Primary Research 141
    Expert Panel Validation 141
    Contact Us 141
    Disclaimer 142

    List of Tables

    Number of Products under Development for Candidiasis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Candidiasis - Pipeline by Amplyx Pharmaceuticals Inc, H1 2017
    Candidiasis - Pipeline by Bakker Medical Srl, H1 2017
    Candidiasis - Pipeline by Biomar Microbial Technologies, H1 2017
    Candidiasis - Pipeline by Biosergen AS, H1 2017
    Candidiasis - Pipeline by Cidara Therapeutics Inc, H1 2017
    Candidiasis - Pipeline by CSA Biotechnologies LLC, H1 2017
    Candidiasis - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
    Candidiasis - Pipeline by Dermala Inc, H1 2017
    Candidiasis - Pipeline by General Biologicals Corp, H1 2017
    Candidiasis - Pipeline by Grupo Ferrer Internacional SA, H1 2017
    Candidiasis - Pipeline by Hsiri Therapeutics LLC, H1 2017
    Candidiasis - Pipeline by iCo Therapeutics Inc., H1 2017
    Candidiasis - Pipeline by ImmunoClin Corp, H1 2017
    Candidiasis - Pipeline by Matinas BioPharma Holdings Inc, H1 2017
    Candidiasis - Pipeline by Nanomerics Ltd, H1 2017
    Candidiasis - Pipeline by NovaDigm Therapeutics Inc, H1 2017
    Candidiasis - Pipeline by Novartis AG, H1 2017
    Candidiasis - Pipeline by Onxeo SA, H1 2017
    Candidiasis - Pipeline by Scynexis Inc, H1 2017
    Candidiasis - Pipeline by Sealife PHARMA GMBH, H1 2017
    Candidiasis - Pipeline by Viamet Pharmaceuticals Inc, H1 2017
    Candidiasis - Pipeline by Visterra Inc, H1 2017
    Candidiasis - Pipeline by Wellstat Vaccines LLC, H1 2017
    Candidiasis - Dormant Projects, H1 2017
    Candidiasis - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Candidiasis - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Candidiasis - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Candidiasis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Top 10 Routes of Administration, H1 2017
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    Amplyx Pharmaceuticals Inc
    Bakker Medical Srl
    Biomar Microbial Technologies
    Biosergen AS
    Cidara Therapeutics Inc
    CSA Biotechnologies LLC
    Daewoong Pharmaceutical Co Ltd
    Dermala Inc
    General Biologicals Corp
    Grupo Ferrer Internacional SA
    Hsiri Therapeutics LLC
    iCo Therapeutics Inc.
    ImmunoClin Corp
    Matinas BioPharma Holdings Inc
    Nanomerics Ltd
    NovaDigm Therapeutics Inc
    Novartis AG
    Onxeo SA
    Scynexis Inc
    Sealife PHARMA GMBH
    Viamet Pharmaceuticals Inc
    Visterra Inc
    Wellstat Vaccines LLC

    Request for Sample

    Report Url http://www.reportsweb.com//candidiasis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//candidiasis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//candidiasis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments